Hepatic cytochrome P-4503A (CYP3A) activity in the elderly
References (41)
Molecular genetics of the P-450 superfamily
Pharm. Ther.
(1990)- et al.
Purification and characterization of hepatic microsomal cytochrome P-450
Pharm. Ther.
(1990) - et al.
The Effect of age on antipyrine metabolism by liver microsomes isolated from phenobarbital-treated rats
Mech. Ageing Dev.
(1989) - et al.
Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
J. Biol. Chem.
(1986) - et al.
Significance of cytochrome P-450 (P-450 HFLa) of hhuman fetal livers in the steroid and drug oxidations
Biochem. Pharm.
(1987) - et al.
Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme
Arch. Biochem. Biophys.
(1988) - et al.
Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450 HLp in the adult
Biochem. Pharm.
(1988) - et al.
Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver
J. Biol. Chem.
(1989) - et al.
Studies on the pregnenolone-16 alpha carbonitrile form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase
Biochem. Pharm.
(1987) - et al.
Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver
Biochem. Pharm.
(1988)
Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P-450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat
Biochem. Biophys. Res. Comm.
Human fetal and adult liver metabolism of ethylmorphine
Biochem. Pharmacol.
Effect of normal aging on the activity of human hepatic cytochrome P-450IIE1
Biochem. Pharm.
Drug disposition in old age
New Engl. J. Med.
Pharmacology and aging
J. Am. Geriatr. Soc.
American Medical Association White Paper on Elderly Health; Report of the Council on Scientific Affairs
Arch. Int. Med.
Pharmacokinetic aspects of drug therapy in the elderly
Ther. Drug Monitoring
Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients
Ann. Int. Med.
The influence of age on the onset of anaesthesia with midazolam
Anaesthesia
Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity
J. Pharm. Exp. Ther.
Cited by (84)
Pharmacokinetics of obese adults: Not only an increase in weight
2023, Biomedicine and PharmacotherapyDose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model
2020, Acta Pharmaceutica Sinica BSex differences in the pharmacology of itch therapies—a narrative review
2019, Current Opinion in PharmacologyThe regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders
2019, Journal of Food and Drug AnalysisCitation Excerpt :Using in-vivo metabolic probes (cocktail substrates for CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A4), the metabolic activities of CYP2C19, CYP2E1, and CYP3A4, but not of CYP1A2 and CYP2D6, seem to be dependent on age [89]. However, the regulation of CYP3A4 expression during aging remains controversial [90,91] and the conditions may vary among aged human individuals due to their personal medical history. In this regard, using normal aging animals may be a promising strategy to clarify the impact of aging on the expression of enzymes/transporters [92,93].
Physiologically based pharmacokinetic modelling to guide drug delivery in older people
2018, Advanced Drug Delivery ReviewsCitation Excerpt :Blanco et al. [32] investigated age related changes in microsomal CYP1A2 (ethoxyresorufin), CYP2E1 (ethoxycoumarin), CYP3A4/5 (midazolam) and CYP2C8 (paclitaxel 17α position) and found no age related change in activity between subjects >60 years compared to those >10 to 59 years. Previously Hunt et al. had also demonstrated no change in CYP3A activity in vitro with age (range 27 to 83 years) [33] and also in vivo using the erythromycin breath test between an older (70 to 88 years) compared to a younger age group (20 to 60 years) [34]. In another study the same authors showed no change in CYP2E1 activity over the range of 30 to 75 years [35].